Bispecific antibodies are molecules that are designed to engage or bind to two distinct targets, bringing two distinct cells together. The majority of those that have received regulatory approval are T-cell-engaging bispecific antibodies. Blinatumomab (Blincyto) for ALL, teclistamab (Tecvayli) for multiple myeloma, and mosunetuzumab-axgb (Lunsumio) for follicular lymphoma are some examples of FDA-approved treatments. Glofitamab, another bispecific antibody, is currently under FDA Priority Review for the treatment of R/R DLBCL. Another type of immunotherapy is chimeric antigen receptor (CAR) T-cell therapy, but bispecific antibodies provide the same spectrum of side effects with much less toxicity and are showing promise in solid tumors as well.